The Briefing provides an at-a-glance view of some important developments in the information universe surrounding COVID-19. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.

Download this Scan

ECRI Horizon Scanning has selected the topics below as those with potential for impact relative to COVID-19 in the United States within the next 12 months. All views presented are preliminary and based on readily available information at the time of writing.

Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders. Topics are listed in alphabetical order.

AZD1222 (ChAdOx1 nCoV-19) Vaccine for Preventing Coronavirus Infection

At a Glance

  • AZD1222 (AstraZeneca, licensed from the University of Oxford) is an investigational adenoviral vector vaccine against novel coronavirus designed to induce protective immune responses
  • In a phase 1/2 study, 10 healthy participants receiving a booster dose of AZD1222 at day 28 had neutralizing antibody levels 4 times higher than those given a single dose
  • AZD1222 is in phase 2/3 development, with results expected in August 2021. The vaccine is part of the US government's Operation Warp Speed and, if early data are promising, it might be available as early as October 2020

BNT162 mRNA Vaccines for Preventing Coronavirus Infection

At a Glance

  • BNT162 mRNA vaccines (Pfizer and BioNTech) represent 3 investigational mRNA vaccine candidates against coronavirus designed to induce protective immune responses
  • In a phase 1/2 study, 45 healthy adults receiving one of the vaccines (BNT162b1) had neutralizing antibody responses 1.8- to 2.8-fold higher than those found in COVID-19 convalescent sera (ie, serum from people who recovered from COVID-19) at 14 days after a second dose
  • BNT162 mRNA vaccines are in phase 1/2 clinical trials, with full results expected in June 2021. However, because the vaccines are part of the US government's Operation Warp Speed, they might be available in some capacity by the end of 2020

We welcome your comments on this Scan. Send them by email to [email protected] or
by mail to: Patient-Centered Outcomes Research Institute, 1828 L Street, NW, Suite 900, Washington, DC 20036.

Commentary in this COVID-19 Scan reflects preliminary views of ECRI Horizon Scanning and internal ECRI stakeholders. The information contained in this document has not been vetted by other stakeholders.


Posted: July 28, 2020

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.

Subscribe to PCORI Emails

Image

Hand pointing to email icon